share_log

Leading Operations Executive Adi Shemer Joins AppYea's Advisory Board

Leading Operations Executive Adi Shemer Joins AppYea's Advisory Board

領先的運營執行阿迪·謝默加入 AppYEA 諮詢委員會
Accesswire ·  2023/02/16 22:26

GAN YAVNE, ISRAEL / February 16, 2023 / AppYea Inc. (OTCQB:APYP), a developer of accurate wearable monitoring solutions to treat sleep apnea and snoring, is pleased to announce the addition of Adi Shemer to the advisory board of the Company, effective immediately.

Gan YAVNE,以色列/2023年2月16日/AppYea Inc.(OTCQB:APYP),一家開發治療睡眠呼吸暫停和鼾症的準確可穿戴式監控解決方案的開發商高興地宣佈,Adi Shemer加入公司顧問委員會,立即生效。

Mr. Shemer brings extensive experience in senior operations, management and control of production processes, establishment, and management of logistics systems. Mr. Shemer established and managed marketing and distribution channels in the USA and Europe, mainly in the field of medical devices. Mr. Shemer has served in key senior executive roles including CEO at TR bike Ltd, CEO at Tzora Active Systems Ltd., and as Director of U.S. Operation at Moving Life Ltd. Mr. Shemer has a BSC degree in industrial and management engineering from Ariel University.

Shemer先生在高級運營、生產流程的管理和控制、物流系統的建立和管理方面擁有豐富的經驗。舍默先生在美國和歐洲建立並管理營銷和分銷渠道,主要是在醫療器械領域。舍默先生曾擔任過一些重要的高級管理職務,包括TR Bike有限公司的首席執行官、Tzora Active Systems有限公司的首席執行官以及Moving Life Ltd.美國業務的董事。舍默先生擁有阿裡爾大學工業和管理工程學士學位。

Mr. Shemer stated, "I am excited to join AppYea and look forward to playing an active role in helping enhance the production and distribution of DreamIT, which I believe will dramatically change the quality of sleep for millions of people across the world. I look forward to contributing my experience in the field of international distribution and logistics, as the company transitions from a development stage to fully commercial operations."

舍默先生說,我很高興加入AppYea,並期待著在幫助提高DreamIt的生產和分銷方面發揮積極作用,我相信這將極大地改變世界各地數百萬人的睡眠質量。隨著該公司從發展階段過渡到完全商業運營,我期待著貢獻我在國際分銷和物流領域的經驗。

Boris (Bary) Molchadsky, Chairman and CEO of AppYea, further noted, "I am pleased to welcome Adi to the advisory board given his successful track record. I am convinced that Adi's experience will be invaluable as we advance our commercial strategy, including the development of new sales and distribution channels. The feedback from the market thus far has been extremely encouraging and we look forward to this next phase in our evolution."

AppYea董事長兼首席執行官鮑裡斯(Bary)莫爾查德斯基進一步指出,鑑於阿迪的成功業績,我很高興歡迎他加入顧問委員會。我相信,隨著我們推進我們的商業戰略,包括開發新的銷售和分銷渠道,阿迪的經驗將是無價的。到目前為止,市場的反饋非常令人鼓舞,我們期待著我們發展的下一個階段。

About SleepX

關於SleepX

SleepX is the research and development subsidiary of AppYea. The Company has developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents. The Company currently focuses its activities on commercialization of its first product, DreamIT.

SleepX是AppYea的研發子公司。該公司開發了一種獨特的產品,用於監測和治療睡眠呼吸暫停和鼾症。這項技術受到幾項國際專利的保護。該公司目前的活動重點是其第一個產品的商業化,DreamIt

About AppYea

關於AppYea

AppYea is a Healthtech company commercializing a breakthrough wearable technology for the treatment of snoring and developing wearable solutions to diagnose and treat sleep apnea. The company's solutions are based on its proprietary IP portfolio of AI and sensing technologies for the tracking and analysis of breathing patterns, vital signs and other physiological parameters during sleep, designed for greater accuracy at lower and affordable cost.

AppYea是一家醫療科技公司,正在商業化一項用於治療鼾症的突破性可穿戴技術,並開發可穿戴解決方案來診斷和治療睡眠呼吸暫停。該公司的解決方案基於其專有技術IP產品組合利用人工智慧和傳感技術跟蹤和分析睡眠期間的呼吸模式、生命體徵和其他生理參數,旨在以更低和負擔得起的成本提高準確性。

Cautionary Note Regarding Forward-Looking Statements

有關前瞻性陳述的注意事項

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of AppYea are subject to many factors including, but not limited to, the sufficiency or working capital and our ability to raise the capital needed to fund our development efforts, timing of product development, FDA approval/clearance of products in development, customer acceptance of our products in the market, the introduction of competitive products, the impact of any product liability or other adverse litigation, commercialization and technological difficulties, and the other risks identified in the S-1 resale registration statement filed with the Securities and Exchange Commission. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

本新聞稿中包含的非歷史性陳述是根據1995年《私人證券訴訟改革法》的安全港條款作出的前瞻性陳述。有關AppYea未來業績的陳述受許多因素的影響,包括但不限於我們的開發努力所需的充足或營運資本和我們籌集資金的能力、產品開發的時間、FDA對正在開發的產品的批准/批准、客戶對我們產品在市場上的接受程度、競爭產品的推出、任何產品責任或其他不利訴訟、商業化和技術困難的影響,以及提交給美國證券交易委員會的S-1轉售註冊聲明中確定的其他風險。這類陳述是基於管理層目前的信念和預期,並受到重大風險和不確定性的影響。實際結果可能與前瞻性陳述中陳述的結果不同。本新聞稿中包含的前瞻性陳述是截至本新聞稿之日作出的,我們不承擔任何義務來更新任何前瞻性陳述,無論是由於未來事件、新資訊或其他原因。

Contact:

聯繫方式:

Crescendo Communications, LLC
Tel: (212) 671-1020
Email: APYP@Crescendo-IR.com

Cresendo Communications,LLC
電話:(212)671-1020
電子郵件:apyp@cresendo-ir.com

SOURCE: AppYea Inc.

資料來源:AppYea Inc.


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論